Law Offices of Thomas J. Lamb

  • Free Case Evaluation
  • Mesothelioma & Asbestos Diseases
  • Legal Compensation
  • Asbestos Overview
  • Common Questions
  • About Our Firm

Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study

February 14, 2022 By Thomas Lamb

Introduction:  Malignant mesothelioma (MM) is an aggressive cancer that primarily arises from the pleura (MPM) or peritoneum (MPeM), mostly due to asbestos exposure. This study reviewed the Dutch population-based incidence, treatment and survival since the national ban on asbestos in 1993. Materials and methods:  Patients with MPM or MPeM … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: asbestos exposure, malignant mesothelioma, mesothelioma, mesothelioma diagnosis, mesothelioma treatments, peritoneal mesothelioma, pleural mesothelioma

Surgical Risk and Survival Associated With Less Invasive Surgery for Malignant Pleural Mesothelioma

January 11, 2022 By Thomas Lamb

We compared less invasive surgery with conventional surgery for malignant pleural mesothelioma (MPM). We retrospectively reviewed consecutive patients with MPM who received surgery at Hyogo College of Medicine between July 2004 and April 2016. Patients underwent multimodal treatment comprising chemotherapy (neoadjuvant and/or adjuvant) and surgery … [Read more...]

Filed Under: Medicine, Mesothelioma, Uncategorized Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Immune Checkpoint Inhibitors Extend Survival for Mesothelioma

December 29, 2021 By Thomas Lamb

Immune checkpoint inhibitor (ICI) therapies have ushered in an exciting new phase of clinical research and treatment for malignant pleural mesothelioma (MPM), offering more effective and less toxic treatment options for patients. The research and clinical oncology communities eagerly await the completion of several upcoming trials focused on … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: Immune checkpoint inhibitor (ICI), malignant pleural mesothelioma (MPM), mesothelioma treatments

Nivolumab plus ipilimumab confers sustained OS benefit in malignant pleural mesothelioma

December 15, 2021 By Thomas Lamb

Nivolumab plus ipilimumab conferred a durable survival benefit compared with chemotherapy as first-line treatment for unresectable malignant pleural mesothelioma, according to randomized phase 3 trial data released by the manufacturer. The open-label, multicenter CheckMate-743 trial included 605 patients who received six cycles of pemetrexed and … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: Ipilimumab, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, Nivolumab

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

December 6, 2021 By Thomas Lamb

INCIDENCE AND EPIDEMIOLOGY Incidence Incidence of malignant pleural mesothelioma (MPM) is generally higher in males than females and is attributed to historical differences in exposures with world-standardised incidence rates per 100,000 persons of 0.7 and 0.3 in the USA and 1.7 and 0.4 for Europe (for males and females, respectively). [ … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant mesothelioma, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma diagnosis, mesothelioma treatments

Imfinzi-Chemo Combo Improves Survival for Mesothelioma

November 19, 2021 By Thomas Lamb

Imfinzi plus platinum-pemetrexed chemotherapy induced survival improvements in patients with previously untreated, unresectable malignant pleural mesothelioma, compared with chemotherapy alone. Treatment with Imfinzi (durvalumab) plus platinum-pemetrexed chemotherapy was associated with improved survival among patients with previously untreated, … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: Imfinzi, malignant mesothelioma, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

November 3, 2021 By Thomas Lamb

Background:  No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy. The aim of this study was to assess the efficacy and safety of nivolumab, an anti-PD-1 antibody, in these patients. Methods:  This was a multicentre, … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant mesothelioma, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, Nivolumab, peritoneal malignant mesothelioma

Immunotherapy combination maintains OS advantage in malignant pleural mesothelioma

October 28, 2021 By Thomas Lamb

The combination of nivolumab and ipilimumab maintained its survival advantage over chemotherapy with at least 3 years of follow-up among patients with unresectable malignant pleural mesothelioma, according to CheckMate 743 study results. Researchers observed the benefit of the first-line immunotherapy regimen despite patients having been off … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: Ipilimumab, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, Nivolumab, Opdivo, Yervoy

Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial

October 21, 2021 By Thomas Lamb

Background:  There is a preclinical rationale for inhibiting angiogenesis in mesothelioma. We aimed to assess the efficacy and safety of the anti-VEGFR-2 antibody ramucirumab combined with gemcitabine in patients with pretreated malignant pleural mesothelioma [ as a second-line treatment ]. Methods:  RAMES was a multicentre, randomised, … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Adding Atezolizumab to Neoadjuvant Cisplatin-Pemetrexed a Feasible Option in Malignant Pleural Mesothelioma

October 15, 2021 By Thomas Lamb

A three-agent neoadjuvant regimen that combines a PD-L1 inhibitor with chemotherapy appears feasible for patients with malignant pleural mesothelioma, according to an ongoing phase I trial. The findings [ about neoadjuvant therapy ] were presented at the International Association for the Study of Lung Cancer virtual World Conference on Lung Cancer, … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

« Previous Page
Next Page »

Do I Have A Possible Case?

If you have a possible asbestos disease or mesothelioma lawsuit, you can get a free, confidential, and no obligation case review from asbestos lawyer Tom Lamb.

Main Navigation Menu

  • Who Was Exposed to Asbestos
  • NC Asbestos Exposure Sites
  • Asbestos-Contaminated Talc
  • Asbestos Diseases
  • Legal Compensation
  • Free Case Evaluation
  • Frequently Asked Questions
  • About Our Law Firm
  • Attorney Tom Lamb
  • Collection of Articles
  • Sitemap

Attorney Tom Lamb

TJL@LambLawOffice.com

Phone: 800-426-9535

Lumina Station, Suite 225
1908 Eastwood Road
Wilmington, North Carolina

Please know that you can use our Quick Contact Form to tell us about your case.

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Website

Lamb Law Office

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2022 · Law Offices of Thomas J. Lamb, P.A.